沃华医药：2025年净利同比预增119.76%-215.90%

Core Viewpoint - Wohua Pharmaceutical (002107.SZ) forecasts a net profit attributable to shareholders of 80 million to 115 million yuan for the year 2025, representing a year-on-year growth of 119.76% to 215.90% [1] Group 1 - The company has seen solid results from its marketing reforms, with a more professional and mature sales team adapting to the competitive landscape following the market entry of its product, Xin Ke Shu Pian [1] - The hospital market has been consolidated and developed, leveraging brand and academic advantages to achieve precise extension and efficient coverage in the external market [1] - The company is building a collaborative development model that integrates both hospital and external markets, with initial scale achieved in external market sales [1]